Stay updated on Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Footer references to Moffitt Cancer Center and the 'Helpful Links' section were removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-18T16:16:14.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2; no substantive changes to the study details are indicated.
    Difference
    0.0%
    Check dated 2026-02-11T14:27:10.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Revision tag updated from v3.4.0 to v3.4.1.
    Difference
    0.0%
    Check dated 2026-02-04T10:32:55.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary display option and updated page metadata to revision v3.4.0, including a new 'No FEAR Act Data' label and revised QC timestamp entries.
    Difference
    0.4%
    Check dated 2026-01-28T06:28:58.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The top of the Study Details page now shows Revision: v3.3.4, replacing the previous Revision: v3.3.3 banner.
    Difference
    0.0%
    Check dated 2026-01-14T03:13:38.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Locations section added showing Florida as a study site; Florida Locations entry and the HHS Vulnerability Disclosure link were removed. Revision: v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T22:23:04.000Z thumbnail image

Stay in the know with updates to Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.